Navigation Links
Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
Date:5/30/2013

New York, New York (PRWEB) May 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, is reporting that Medtronic has revealed that a long-awaited independent review of its Infuse bone graft products will be available soon. As HealthPointCapital reported on May 23, 2013, the results of a Yale-commissioned review of Medtronic’s Infuse products will be released in June. Medtronic approached Yale University researchers after a June 2011 study published in The Spine Journal disclosed that Medtronic-paid researchers had failed to report serious potential complications from use of Infuse bone graft products in spinal surgery.

The U.S. Food and Drug Administration (FDA) approved Infuse in 2002 for use in fusing damaged vertebrae in the lower spine; Infuse was not approved for use on the upper, or cervical, spine, where it is now widely used, according to an Oct. 25, 2012 Bloomberg Businessweek report. In fact, the report added, the FDA released a July 1, 2008 notification warning that the Infuse Bone Graft had been associated with serious complications – including excessive swelling in the neck, compressed airways, difficulty breathing, problems swallowing and nerve damage – when used in cervical spinal fusions.

“We look forward to the release of the Infuse study by Yale University,” said Gary Falkowitz, Managing Attorney at Parker Waichman LLP. “At the very least it should be quite revealing to see what an independent report on these potentially dangerous products has to say.”

Only last fall, as noted by the Bloomberg Businessweek report, the U.S. Senate Finance Committee found problems with most of the initial Medtronic-supported Infuse research used to promote the product. The article noted that doctors and researchers who authored at least 11 medical journal reports about Infuse were paid about $210 million in royalties and consulting fees. Senate investigators also charged that Medtronic deliberately manipulated studies to mitigate any adverse reactions to Infuse side effects, as well as to promote off-label use.

“Medtronic’s actions violate the trust patients have in their medical care,” Senator Max Baucus, a Montana Democrat and committee chairman, said in a statement, quoted in the article. “Medical journal articles should convey an accurate picture of the risks and benefits of drugs and medical devices, but patients are at serious risk when companies distort the facts the way Medtronic has.”

Parker Waichman LLP is currently offering free legal consultations to victims of Medtronic Infuse Bone Graft Injuries. If you or a loved one suffered a serious complication or injury after receiving Medtronic Infuse, please contact their office by visiting the firm's Medtronic Infuse injury page at yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/medtronic_yale_study/05/prweb10786396.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
2. Chase Attorneys Offer Free Consultations
3. Medtronic Voted the Most Sought-After Employer by MedReps.com Community
4. Medtronic Infuse bone-graft lawsuit consultation referrals offered by Resource4thePeople
5. 2013 Cases Involving Medtronic Infuse Bone Graft Failure Allegations Now Being Investigated by Resource4thePeople Lawyers
6. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
7. Medtronic Infuse Bone Graft Failure Allegation Lawsuits Information Bank for Consumers Now Available through Resource4thePeople
8. Medtronic Infuse Lawsuit News: Bernstein Liebhard LLP Awaits Expected Release of Medtronic-Commissioned Analysis of Infuse Bone Graft Trials
9. Medtronic Takes the Lead in the US Spinal Implant Market, Reports iData Research
10. Ready for debut: Fruit-juice-infused chocolate with 50 percent less fat
11. Moringa Source Launches Natura Veda™, an Age-Defying, All-Natural Skin Care System Infused with Moringa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated ... , Gary D. Radine, who recently retired as president and CEO of Delta Dental ... 2015 CEO of the Year , helped lead the effort to raise funds for ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically known ... approved FDA injectable medication used as a non-surgical alternative for reduction of fat ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, Inc. ... genome editing, announced that the U.S. Food and ... New Drug (IND) application for SB-318, a single ... for Mucopolysaccharidosis Type I (MPS I). The SB-318 ... to initiate a Phase 1/2 clinical study (SB-318-1502) ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: